Lobomycosis or lobo disease is a persistent fungal skin and subcutaneous tissue infection that is most common in Latin American tropical settings. Lacazia loboi (previously Loboa loboi), a dimorphic fungus found in soil, vegetation, and water, is the causal organism. Infection arises as a result of the fungus's forceful implantation into the skin.
- Slow-growing, keloid-like papules, nodules, or plaques in a limited area on exposed skin are the most prevalent presentation in people.
- Lobomycosis can also appear as ulcerated, infiltrative, verrucous, gumma-like, multifocal, or disseminated lesions.
- Since lobomycosis is the established title for this condition, it has been known by many different other names.
- Jorge Lobo's disease, Jorge Lobo mycosis, Jorge Lobo blastomycosis, Amazonic pseudolepromatous blastomycosis, miraip or piraip ("burning" in Tupi), Caiabi leprosy, and lacaziosis are among examples.
- This disease has no established treatment. Although a broad surgical excision for small, well-defined early lesions may be successful, relapses are common.
- The therapy of choice is surgical excision or cryosurgery.
- Although antifungal treatment has been deemed ineffectual, the use of clofazimine and dapsone in individuals with leprosy and lobomycosis has been shown to ameliorate the latter. This therapy regimen has been utilized to prevent recurrence following surgery, in conjunction with itraconazole.
- Both surgical excision and cryotherapy have been reported efficient for lobomycosis.
- Successful medications include clofazimine, itraconazole, and multibacillary therapy for leprosy.
Slow-growing, keloid-like papules, nodules, or plaques in a limited area on exposed skin